Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 7, 2001, Pages 452-455

  Suryanarayan, Kaveri ^a   Natkunam, Yasodha ^a   Berry, Gerald ^a   Bangs, Charles D ^a   Cherry, Athena ^a   Dahl, Gary ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Pediatrics; Posttransplantation lymphoproliferative disease

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; FOLINIC ACID; HYDROXYDAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FOLLOW UP; HUMAN; INFANT; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; SEPSIS; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASM STAGING; ORGAN TRANSPLANTATION; PREDNISONE; VINCRISTINE;

EID: 0034760603     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200110000-00012     Document Type: Article

References (30)

1. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 3091-3.
2. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438-42.
3. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106-12.
4. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-9.
5. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987; 5: 1673-89.
6. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-72.
7. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-79.
8. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-92.
9. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770-9.
10. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-7.
11. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-8.
12. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241-4.
13. Liebowitz D, Anastasi J, Hagos F, et al. Post-transplant lymphoproliferative disorders (PTLD): Clinicopathologic characterization and response to immunomodulatory therapy with interferon-alpha. Ann Oncol 1996; 7 (S3): 28.
14. Cantarovich M, Barkun JS, Forbes RD, et al. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 1998; 12: 109-15.
15. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-6.
16. Nalesnik MA. Involvement of the gastrointestinal tract by Epstein-Barr virus- associated posttransplant lymphoproliferative disorders. Am J Surg Pathol 1990; 14 (S1): 92-100.
17. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment of postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333-40.
18. Swinnen LJ. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 1997; 28: 89-101.
19. Gross TG, Hinrichs SH, Winner J, et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy [letter]. Ann Oncol 1998; 9: 339-40.
20. Balfour IC, Wall D, Luisiri A, et al. Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. J Heart Lung Transplant 1999; 18: 492-5.
21. Praghakaran K, Wise B, Chen A, et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999;34:1115-6, 1125.
22. Ladanyi M, Offit K, Jhanwar SC, et al. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas Blood 1991, 77: 1057-63.
23. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8-14.
24. Kamel OW, Chang PP, Hsu FJ, et al. Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classic Hodgkin’s disease. Am J Clin Pathol 1995; 104: 419-23.
25. Natkunam Y, Warnke RA, Zehnder JL, et al. Aggressive natural killer-like T-cell malignancy with leukemic presentation following solid organ transplantation. Am J Clin Pathol 1999; 111: 663-71.
26. van de Rijn M, Cleary ML, Variakojis D, et al. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 638-42.
27. Murphy SB. Prognostic features and obstacles to cure of childhood non-Hodgkin’s lymphoma. Semin Oncol 1977; 4: 265-71.
28. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294-302.
29. Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood 1999; 93: 2167-72.
30. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-62.